chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Fatigue
Clinical narrative: Very very tired; No energy; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 23Apr2021 at 16:15 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included lyme disease. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. Concomitant medications were not reported. On an unknown date in Apr2021, the patient was very very tired and had no energy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very very tired and no energy was resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Menstruation delayed
Clinical narrative: Menstrual cycle is a week late (not sexually active and no other life changes); Getting period cramps sans the bleeding; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 at 13:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to cinnamon. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medication within two weeks of vaccination. On 20Apr2021, the patient experienced menstrual cycle is a week late (not sexually active and no other life changes) and getting period cramps sans the bleeding. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events menstrual cycle is a week late (not sexually active and no other life changes) and getting period cramps sans the bleeding was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Chills, Myalgia
Clinical narrative: Subject reported muscle aches within 24 hours of receiving the vaccine; Subject reported muscle aches and chills within 24 hours of receiving the vaccine; This is a spontaneous report from a contactable consumer. A 37-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on an unknown date in Apr2021 as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medications within two weeks of vaccination. On an unknown date in Apr2021, the patient experienced, muscle aches and chills within 24 hours of receiving the vaccine. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle aches and chills were recovered on an unknown date in Apr 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Oral mucosal eruption, Pruritus, Pyrexia, Rash
Clinical narrative: Fever sweats for about an hour; Shortly after I got a rash around my mouth; Shortly after I got a rash around my mouth and on my left elbow.; Hive like very itchy no pain; A bit of fever; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 13Apr2021 at 15:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma due to allergies, heart surgery in 1996 and the patient was allergic to sulfa and gluten. Concomitant medications included amoxicillin (MANUFACTURER UNKNOWN) from unknown date for unknown indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the night of shot, the patient had a bit of fever. Next morning, on 14Apr2021 at 09:30 the patient had fever sweats for about an hour, felt like body was over heating. Shortly after that the patient got a rash around her mouth and on her left elbow. Elbow healed quickly, mouth rash lasted a week and the patient was around the corner of her mouth and chin. The patient also had hive like very itchy no pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events got a rash around mouth and on left elbow and had hive like very itchy no pain which included treatment with diphenhydramine hydrochloride (BENADRYL). Since the vaccination, the patient had been tested for COVID-19. On 14Apr2021, patient underwent SARS-CoV-2 test via nasal swab and the result was negative. The clinical outcome of the event shortly after got a rash around mouth was resolved on 21Apr2021. The clinical outcome of the events a bit of fever, fever sweats for about an hour, shortly after got a rash around mouth and on left elbow, hive like very itchy no pain was resolved on unknown date on Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Fever sweats for about an hour; Shortly after I got a rash around my mouth; Shortly after I got a rash around my mouth and on my left elbow.; Hive like very itchy no pain; A bit of fever; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 13Apr2021 at 15:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma due to allergies, heart surgery in 1996 and the patient was allergic to sulfa and gluten. Concomitant medications included amoxicillin (MANUFACTURER UNKNOWN) from unknown date for unknown indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021, the night of shot, the patient had a bit of fever. Next morning, on 14Apr2021 at 09:30 the patient had fever sweats for about an hour, felt like body was over heating. Shortly after that the patient got a rash around her mouth and on her left elbow. Elbow healed quickly, mouth rash lasted a week and the patient was around the corner of her mouth and chin. The patient also had hive like very itchy no pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events got a rash around mouth and on left elbow and had hive like very itchy no pain which included treatment with diphenhydramine hydrochloride (BENADRYL). Since the vaccination, the patient had been tested for COVID-19. On 14Apr2021, patient underwent SARS-CoV-2 test via nasal swab and the result was negative. The clinical outcome of the event shortly after got a rash around mouth was resolved on 21Apr2021. The clinical outcome of the events a bit of fever, fever sweats for about an hour, shortly after got a rash around mouth and on left elbow, hive like very itchy no pain was resolved on unknown date on Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Dizziness, Fatigue, Feeling abnormal
Clinical narrative: Migraine; Sore arm; Began to feel weak; Foggy headed/foggy headedfeeling; feel even more tired./ I still struggle with fatigue; Vertigo; Dizziness; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 08Apr2021 at 13:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included liver hemangioma and acid reflux. Patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included omeprazole (PRILOSEC) and multivitamin (MANUFACTURER UNKNOWN); both from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021, within 5 minutes of receiving the vaccine, the patient began to feel weak and foggy headed, later on the day she had a sore arm and felt even more tired, 24 hours after the vaccine she had a migraine lasting about 12 hours, 2.5 weeks after the vaccine she still struggled with fatigue, vertigo/dizziness, "foggy" headed feeling, and joint pain. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event migraine was resolved after 12 hours on an unknown date in Apr2021; while that of the events began to feel weak, foggy headed, sore arm, tired / struggle with fatigue, vertigo, dizziness and joint pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Pain in extremity, Vertigo
Clinical narrative: Migraine; Sore arm; Began to feel weak; Foggy headed/foggy headedfeeling; feel even more tired./ I still struggle with fatigue; Vertigo; Dizziness; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 08Apr2021 at 13:30 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included liver hemangioma and acid reflux. Patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included omeprazole (PRILOSEC) and multivitamin (MANUFACTURER UNKNOWN); both from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021, within 5 minutes of receiving the vaccine, the patient began to feel weak and foggy headed, later on the day she had a sore arm and felt even more tired, 24 hours after the vaccine she had a migraine lasting about 12 hours, 2.5 weeks after the vaccine she still struggled with fatigue, vertigo/dizziness, "foggy" headed feeling, and joint pain. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event migraine was resolved after 12 hours on an unknown date in Apr2021; while that of the events began to feel weak, foggy headed, sore arm, tired / struggle with fatigue, vertigo, dizziness and joint pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Headache, Movement disorder
Clinical narrative: High fever (104.5); uncontrollable chills; joints from head to toes severe pain( practically could not move); practically could not move; headache; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 23Apr2021 at 14:30 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and allergies to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other unspecified medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 02Apr2021 at 14:30 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 02:00, the patient experienced high fever (104.5), uncontrollable chills, joints from head to toes severe pain, practically could not move and headache. On 24Apr2021, the patient underwent lab tests and procedures which included body temperature test and the result was found to be high fever of 104.5 (unspecified units). The events did not result in doctor or other health care professional office or clinic visit and emergency room department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high fever (104.5), uncontrollable chills, joints from head to toes severe pain, practically could not move and headache were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: High fever (104.5); uncontrollable chills; joints from head to toes severe pain( practically could not move); practically could not move; headache; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration in the left arm on 23Apr2021 at 14:30 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and allergies to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other unspecified medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 02Apr2021 at 14:30 (at the age of 54-year-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 02:00, the patient experienced high fever (104.5), uncontrollable chills, joints from head to toes severe pain, practically could not move and headache. On 24Apr2021, the patient underwent lab tests and procedures which included body temperature test and the result was found to be high fever of 104.5 (unspecified units). The events did not result in doctor or other health care professional office or clinic visit and emergency room department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high fever (104.5), uncontrollable chills, joints from head to toes severe pain, practically could not move and headache were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Fatigue, Pain, Palpitations
Clinical narrative: Pain in upper back; Heart palpitations; Body aches; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8736) via an unspecified route of administration in the left arm on 25Apr2021 at 14:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route of administration on 04Apr2021 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. On 26Apr2021 at 13:30, the patient experienced pain in upper back, heart palpitations, body aches and fatigue. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. The clinical outcome of the events pain in upper back, heart palpitations, body aches and fatigue were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, UNK
Symptoms: Malaise
Clinical narrative: felt terrible; This is a spontaneous report via contactable other HCP (patient). A 70-year-old female patient received bnt162b2 (BNT162B2 formulation; Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE NUMBER UNKNOWN, SINGLE for COVID-19 immunisation. The patient received tofacitinib citrate (XELJANZ XR Prolonged-release tablet), oral from unknown date of 2017 (Batch/Lot number was not reported) and ongoing, at 11 mg, once daily for rheumatoid arthritis. Medical history included ongoing rheumatoid arthritis. The patient's concomitant medications were not reported. The patient stated stopping xeljanz for 4 to 5 days before and 4 to 5 days after received covid vaccine. The patient felt terrible on an unspecified date after receiving the vaccine and was unsure if it was related to the vaccine or stopping xeljanz. The patient stated she did not have any joint inflammation during the time she stopped xeljanz and unsure if MD aware. The action taken in response to the event for tofacitinib citrate was dose not changed. The outcome of event was unknown.  No follow-up attempts are needed. information about lot/batch number cannot be obtained.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Severe headaches starting a week after shot; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 11Apr2021 at 13:15 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis and interstitial lung disease. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), mycophenolate mofetil (MYCOPHENOLATE), levothyroxine sodium (SYNTHROID) and prednisone (MANUFACTURER UNKNOWN); all from unknown date for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 21Mar2021 at 13:15 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021, the patient experienced severe headaches starting a week after shot. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe headaches starting a week after shot was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Blood pressure increased, Blood pressure measurement, Dizziness
Clinical narrative: Lightheaded and dizziness; Blood pressure was elevated; Anxiety; This is a spontaneous report from a contactable pharmacist. A 47-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via intramuscular route of administration in the left arm on 14Apr2021 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included transient ischaemic attack (TIA). The patient had known allergies to sulfa antibiotics and avocados. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included lorazepam (ATIVAN); taken for an unknown indication from an unknown date and unknown if ongoing. On 14Apr2021, the patient reported lightheaded and dizziness, blood pressure was elevated. The patient reported improvement of symptoms. Education was provided for blood pressure and anxiety. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 14Apr2021, the patient underwent blood pressure test and the result was elevated. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lightheaded and dizziness, blood pressure was elevated and anxiety was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Asthenia, Dizziness, Eye pain, Headache
Clinical narrative: Very strong dizziness; stomachache pain; Fever; Trowed up; Headache; weakness; Eyes pain; Pain; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 23Apr2021 at 16:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks prior to the vaccination. On 23Apr2021 at 15:45, the patient experienced very strong dizziness, stomach-ache, pain, fever, trowed up (vomit), headache, weakness and eyes pain. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very strong dizziness, stomach-ache, pain, fever, trowed up (vomit), headache, weakness and eyes pain were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vomiting
Clinical narrative: Very strong dizziness; stomachache pain; Fever; Trowed up; Headache; weakness; Eyes pain; Pain; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 23Apr2021 at 16:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks prior to the vaccination. On 23Apr2021 at 15:45, the patient experienced very strong dizziness, stomach-ache, pain, fever, trowed up (vomit), headache, weakness and eyes pain. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very strong dizziness, stomach-ache, pain, fever, trowed up (vomit), headache, weakness and eyes pain were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal distension, Chills, Constipation, Headache, Myalgia
Clinical narrative: Chills; sore muscles; Headache; Bloating; Constipation; This is a spontaneous report from a non-contactable consumer, the patient. A 19-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER8736) via an unspecified route of administration in the left arm on 25Apr2021 at 10:00 (at the age of 19-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included fluoxetine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 25Apr2021 at 22:00, the patient experienced chills, sore muscles, headache and bloating/constipation. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event chills, sore muscles, headache and bloating/constipation was resolving at this time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Neck pain
Clinical narrative: Pain in right shoulder and neck since about 4 hours or so after receiving the vaccination and has not gone away to this point; Pain in right shoulder and neck since about 4 hours or so after receiving the vaccination and has not gone away to this point.; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non- pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the right arm on 09Apr2021 at 09:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified medications; from an unknown date for an unknown indication and unknown if ongoing. On 09Apr2021 at 14:00, the patient experienced pain in right shoulder and neck since about 4 hours or so after receiving the vaccination and has not gone away to this point. It was unknown if the patient received any treatment for the events. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in right shoulder and neck since about 4 hours or so after receiving the vaccination and has not gone away to this point was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hyperhidrosis, Neuralgia, Pyrexia
Clinical narrative: Extreme fatigue; Headache; Whole body nerve pain; Sweating/fever; Sweating/fever; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Apr2021 at 15:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis. The patient did not take any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 29Apr2021 at 14:00, the patient experienced extreme fatigue, headache, whole body nerve pain and sweating/fever. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fatigue, headache, whole body nerve pain and sweating/fever was not resolved at the time of the report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Heavy menstrual bleeding, Menstruation irregular, Muscle spasms
Clinical narrative: Started period 2 weeks early; Started period 2 weeks early, very heavy bleeding; Bad cramping; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date in 2021 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 15Mar2021 at 09:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 09:00, the patient started period 2 weeks early, very heavy bleeding, bad cramping and very unusual. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events started period 2 weeks early, very heavy bleeding, bad cramping was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Hypertension, Ventricular extrasystoles
Clinical narrative: premature ventricular contractions; High Blood pressure; This is a spontaneous report from a non-contactable consumer, the patient. A 51-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 51-year-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Apr2021, the patient experienced high blood pressure and premature ventricular contractions. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high blood pressure and premature ventricular contractions was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pyrexia
Clinical narrative: Severe body aches; Headache; Queasiness; Fever, lasting through three days after the vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 20-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 23Apr2021 at 09:30 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Medical history included inflammatory arthritis, COVID-19 ( Prior to vaccination, the patient was diagnosed with COVID-19) and sulfonamide allergy(sulfa).Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 16:30 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 the patient experienced severe body aches, headache, queasiness, fever, lasting through three days after the vaccine. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe body aches, headache, queasiness, fever, lasting through three days after the vaccine was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain in extremity, Pyrexia
Clinical narrative: Pain in arm; Shivering; Fever; Tiredness; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Apr2021 at 09:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included telmisartan (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 21:00, the patient experienced pain in arm, shivering, fever and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with paracetamol (TYLENOL). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in arm, shivering, fever and tiredness was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Formication, Rash, Rash papular, Rash pruritic, SARS-CoV-2 test
Clinical narrative: Rash that starts at injection site and spreads throughout the body, across shoulder, up into face and down torso; Rash that starts at injection site and spreads throughout the body, across shoulder, up into face and down torso; Many raised itchy bumps, that look chicken pox like; Many raised itchy bumps, that look chicken pox like; Sensation of 'skin crawling'; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 15:30 (at the age of 44-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 15:15 (at the age of 44-years-old), as single doses for COVID-19 immunisation. Medical history included latex allergy. Prior to the vaccination, the patient had been tested for COVID-19 but she was not diagnosed with COVID-19. On 10Mar2021, the patient underwent SARS-CoV-2 test via nasal swab and the result was found to be negative. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received sumatriptan succinate (IMITREX) on an unknown date and experienced drug allergy. On 03Apr2021 at 00:00, the patient experienced rash that started at injection site and that spread throughout the body, across shoulder, up into face and down torso. The patient also experienced many raised itchy bumps, that looked chicken pox like and the patient had sensation of 'skin crawling'. The patient had same effect for both doses. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with topical steroid (unspecified). The clinical outcome of the events rash that starts at injection site and spreads throughout the body, across shoulder up into face and down torso, many raised itchy bumps, that look chicken pox like and sensation of 'skin crawling" was recovered on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Rash that starts at injection site and spreads throughout the body, across shoulder, up into face and down torso; Rash that starts at injection site and spreads throughout the body, across shoulder, up into face and down torso; Many raised itchy bumps, that look chicken pox like; Many raised itchy bumps, that look chicken pox like; Sensation of 'skin crawling'; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 15:30 (at the age of 44-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 15:15 (at the age of 44-years-old), as single doses for COVID-19 immunisation. Medical history included latex allergy. Prior to the vaccination, the patient had been tested for COVID-19 but she was not diagnosed with COVID-19. On 10Mar2021, the patient underwent SARS-CoV-2 test via nasal swab and the result was found to be negative. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received sumatriptan succinate (IMITREX) on an unknown date and experienced drug allergy. On 03Apr2021 at 00:00, the patient experienced rash that started at injection site and that spread throughout the body, across shoulder, up into face and down torso. The patient also experienced many raised itchy bumps, that looked chicken pox like and the patient had sensation of 'skin crawling'. The patient had same effect for both doses. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with topical steroid (unspecified). The clinical outcome of the events rash that starts at injection site and spreads throughout the body, across shoulder up into face and down torso, many raised itchy bumps, that look chicken pox like and sensation of 'skin crawling" was recovered on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Chills, Disturbance in attention, Fatigue, Vaccination site pain
Clinical narrative: First 12 hours- slight tiredness, 24 hours- extreme tiredness; Hard to focus when 'I'm' most tired; Pain at injection site; Chills; Anxiousness; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 11:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included depression and allergy to fresh apples and fresh cherries. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 13:00, for first 12 hours the patient experienced slight tiredness and 24 hours extreme tiredness, hard to focus when the patient was most tired, pain at injection site, chills and anxiousness. 48 hours the patient had slight pain at injection site, tiredness and anxiousness. 72 hours (also reported as currently), the patient experienced tiredness and anxiousness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events first 12 hours slight tiredness, 24 hours extreme tiredness, hard to focus when most tired, pain at injection site, chills and anxiousness was not resolved at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Pyrexia, Vaccination site pain
Clinical narrative: Fatigue; Fever 101F; Soreness at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration on 19Apr2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cyanocobalamin (VITAMIN B 12) and colecalciferol (VITAMIN D3); both for an unknown indication from an unknown date and unknown if ongoing. On 20Apr2021, approximately 12 hours after vaccination, the patient experienced fatigue, fever 101F, soreness at injection site lasting until 36 hours after vaccination. On the same day, the patient underwent a body temperature test and the result was 101 degrees Fahrenheit. The events did not result in doctor or other health care professional office/clinic visits, and the emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, fever 101F and soreness at injection site was recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Moderate vertigo; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On an unknown date the patient experienced moderate vertigo. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event moderate vertigo was recovered on an unknown date.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.